Trial reportScientific reports2021
Rhamnan sulphate from green algae Monostroma nitidum improves constipation with gut microbiome alteration in double-blind placebo-controlled trial.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Sepsis-induced endothelial glycocalyx disruption and remodeling: an ultrastructural study in mice.Intensive care medicine experimental · 2026Article
- Orally Administered Rhamnan Sulfate fromMarine drugs · 2026Article
- Marine-Algal-Derived Postbiotics Modulating the Gut Microbiota-Adipose Tissue Axis in Obesity: A New Frontier.Nutrients · 2025Review
- Rhamnan Sulfate from the SeaweedMarine drugs · 2025Article
- Gut-brain axis mediated by intestinal content microbiota was associated with Zhishi Daozhi decoction on constipation.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Lipid- and glucose-lowering effects of Rhamnan sulphate fromFood science & nutrition · 2024Article
- Protecting the endothelial glycocalyx in COVID-19.PLoS pathogens · 2024Article
- Oral Administration of Rhamnan Sulfate fromCells · 2023Article
- Fermented Bamboo Fiber Improves Productive Performance by Regulating Gut Microbiota and Inhibiting Chronic Inflammation of Sows and Piglets during Late Gestation and Lactation.Microbiology spectrum · 2023Article
- The utility of algae as sources of high value nutritional ingredients, particularly for alternative/complementary proteins to improve human health.Frontiers in nutrition · 2023Review
- Beneficial effects of seaweed-derived components on metabolic syndrome via gut microbiota modulation.Frontiers in nutrition · 2023Review
- Dietary Polysaccharides as Modulators of the Gut Microbiota Ecosystem: An Update on Their Impact on Health.Nutrients · 2022Review
- Anti-Inflammatory Activity of Orally AdministeredMarine drugs · 2022Article
- Similarities and differences in constipation phenotypes between Lep knockout mice and high fat diet-induced obesity mice.PloS one · 2022Article
- Effects of Hitoegusa (Monostroma nitidum) Extracts on In Vitro Rumen Fermentation Profiles.Animal science journal = Nihon chikusan GakkaihoArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhamnan sulphate (RS), a sulphated polysaccharide from Monostroma nitidum, possesses several biological properties that help in treating diseases such as viral infection, thrombosis, and obesity. In the present study, we first administered RS (0.25 mg/g food volume) orally to high-fat diet-treated mice for 4 weeks. RS increased the faecal volume and calorie excretion with decreased plasma lipids, which was in accordance with the results of our previous zebrafish study. Notably, as the excretion amount by RS increased in the mice, we hypothesised that RS could decrease the chance of constipation in mice and also in human subjects because RS is considered as a dietary fibre. We administrated RS (100 mg/day) to subjects with low defaecation frequencies (3-5 times/week) for 2 weeks in double-blind placebo-controlled manner. As a result, RS administration significantly increased the frequency of dejection without any side effects, although no effect was observed on the body weight and blood lipids. Moreover, we performed 16s rRNA-seq analysis of the gut microbiota in these subjects. Metagenomics profiling using PICRUSt revealed functional alternation of the KEGG pathways, which could be involved in the therapeutic effect of RS for constipation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.